Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798663 | 0.97 | FAAH (0.42) | FAAHSYKBRD4SPHK1SPHK2 | |
| SCHEMBL2801187 | 0.90 | BRD4 (0.47) | FAAHSYKBRD4OPRD1 | |
| SCHEMBL4924459 | 0.87 | BRD4 (0.38) | FAAHSYKBRD4KDM4EMEN1 | |
| SCHEMBL4924585 | 0.82 | ALDH1A1 (0.36) | KDM4EMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL14089392 | 0.81 | CHRNB4 (0.41) | — | |
| SCHEMBL2797321 | 0.79 | CPT1A (0.36) | KDM4EMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL5735308 | 0.79 | SPHK2 (0.43) | SPHK1SPHK2 | |
| SCHEMBL3520472 | 0.79 | SPHK2 (0.43) | SPHK1SPHK2 | |
| SCHEMBL3187133 | 0.74 | NPC1 (0.44) | KDM4EHSD17B10PARP1 | |
| SCHEMBL30353899 | 0.74 | NPC1 (0.44) | KDM4EHSD17B10PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194556-A1 | Quinazolines and Their Use as Aurora Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1888572-A1 | QUINAZOLINES AND THEIR USE AS AURORA KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006129064-A1 | QUINAZOLINES AND THEIR USE AS AURORA KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194556-A1 | Quinazolines and Their Use as Aurora Kinase Inhibitors | AURKA, AURKC, AURKB | FAAH 4376/4885SYK 1206/4885BRD4 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.